Correlation Between Monopar Therapeutics and Unicycive Therapeutics
Can any of the company-specific risk be diversified away by investing in both Monopar Therapeutics and Unicycive Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Monopar Therapeutics and Unicycive Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Monopar Therapeutics and Unicycive Therapeutics, you can compare the effects of market volatilities on Monopar Therapeutics and Unicycive Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Monopar Therapeutics with a short position of Unicycive Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Monopar Therapeutics and Unicycive Therapeutics.
Diversification Opportunities for Monopar Therapeutics and Unicycive Therapeutics
0.77 | Correlation Coefficient |
Poor diversification
The 3 months correlation between Monopar and Unicycive is 0.77. Overlapping area represents the amount of risk that can be diversified away by holding Monopar Therapeutics and Unicycive Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Unicycive Therapeutics and Monopar Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Monopar Therapeutics are associated (or correlated) with Unicycive Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Unicycive Therapeutics has no effect on the direction of Monopar Therapeutics i.e., Monopar Therapeutics and Unicycive Therapeutics go up and down completely randomly.
Pair Corralation between Monopar Therapeutics and Unicycive Therapeutics
Given the investment horizon of 90 days Monopar Therapeutics is expected to generate 1.08 times less return on investment than Unicycive Therapeutics. In addition to that, Monopar Therapeutics is 1.03 times more volatile than Unicycive Therapeutics. It trades about 0.09 of its total potential returns per unit of risk. Unicycive Therapeutics is currently generating about 0.1 per unit of volatility. If you would invest 50.00 in Unicycive Therapeutics on August 28, 2024 and sell it today you would earn a total of 5.00 from holding Unicycive Therapeutics or generate 10.0% return on investment over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Together |
| Strength | Significant |
| Accuracy | 100.0% |
| Values | Daily Returns |
Monopar Therapeutics vs. Unicycive Therapeutics
Performance |
| Timeline |
| Monopar Therapeutics |
| Unicycive Therapeutics |
Monopar Therapeutics and Unicycive Therapeutics Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Monopar Therapeutics and Unicycive Therapeutics
The main advantage of trading using opposite Monopar Therapeutics and Unicycive Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Monopar Therapeutics position performs unexpectedly, Unicycive Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Unicycive Therapeutics will offset losses from the drop in Unicycive Therapeutics' long position.| Monopar Therapeutics vs. Eliem Therapeutics | Monopar Therapeutics vs. HCW Biologics | Monopar Therapeutics vs. Scpharmaceuticals | Monopar Therapeutics vs. Milestone Pharmaceuticals |
| Unicycive Therapeutics vs. Eliem Therapeutics | Unicycive Therapeutics vs. HCW Biologics | Unicycive Therapeutics vs. Scpharmaceuticals | Unicycive Therapeutics vs. Milestone Pharmaceuticals |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Other Complementary Tools
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Equity Valuation Check real value of public entities based on technical and fundamental data |